Mr. Kym Anthony reports

AVIVAGEN ANNOUNCES SIGNIFICANT INCREASE IN SALES TO AN EXISTING CUSTOMER

An existing customer of Avivagen Inc. has placed an order sized at 400 per cent of its normal monthly order volume.

Based in Southeast Asia, the long-established customer with a recurring monthly order of 100 kilograms has increased its coming order for June to 400 kilograms, demonstrating both the increased demand and traction OxC-beta has gained within this region.

"We have seen a number of our customers increase their orders as they become more familiar with Avivagen's product, its use cases and utility and believe this model can be replicated around the world. We are showcasing this potential as we move through our strategic review process, led by the special committee of the board," said Kym Anthony, chief executive officer of Avivagen.

About OxC-beta technology and OxC-beta Livestock

Avivagen's OxC-beta technology is derived from Avivagen discoveries about beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function, the technology provides a non-antibiotic means of promoting health and growth. OxC-beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Mexico, the Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. OxC-beta has been fed to over 46.6 million food animals (poultry, swine and dairy cattle), 133,820 dogs and 4,000 people.

Avivagen's OxC-beta Livestock product is safe and effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proved that the product performs as well as and, sometimes, in some aspects, better than in-feed antibiotics.